Retroperitoneal lymph node dissection (RPLND) is the standard of care for testicular cancer in various disease settings. Deep vein thrombosis (DVT) complications have been reported to occur in <1% of primary RPLND cases and up to 3% of postchemotherapy (PC-RPLND) cases.
While prophylactic anticoagulation (AC) has been well-documented to reduce DVT rates in patients undergoing surgery in general, the benefit of prophylactic AC in RPLND has not been assessed. In this retrospective cohort study, we seek to address this unmet need by evaluating the rates and associated risk factors of DVT and pulmonary embolism (PE) with a national and institutional database, assess the changing patterns in DVT prophylaxis with postoperative AC following RPLND, and quantify the potential benefit of prophylactic AC in patients who have undergone RPLND using a risk-stratified approach.
The National Surgical Quality Improvement Program (NSQIP) database was queried for patients who underwent RPLND during the 10-year period from 2011 to 2021. An institutional database was queried for all patients undergoing RPLND from 2013 to 2022. Patient characteristics and operative outcomes were compared between the NSQIP and the institutional database. The institutional database was stratified by prior oncologic treatment (i.e., primary RPLND vs. PC-RPLND) and outcomes were compared. Postoperative AC rate was determined and trended by year. The use of postoperative AC and PE events were stratified by clinical stage. The absolute risk reduction (ARR) of AC prophylaxis on PE events and the number needed to treat (NNT) with AC prophylaxis to prevent a single PE event was determined.
In total, the NSQIP database query resulted in 779 patients and our institutional database query resulted in 188 patients. The rate of DVT and PE was 1.2% and 0.5% vs. 2.1% and 1.6% in the NSQIP and institutional cohort, respectively. The rate of postoperative AC following RPLND in patients from the institutional database increased from 5% in 2013 to 43% in 2022 (P = 0.01). There were no statistically significant differences in complication rates, including bleeding events, chyle leaks, or hospital readmissions amongst patients who were prescribed AC at discharge and those who were not. No stage I patients developed PEs and no stage I patients were prescribed AC. The ARR for AC prophylaxis for development of PE was found to be 0.023 for the clinical stage II and stage III cohorts. The NNT to prevent a single PE with AC was 44 and 43 for the stage II and stage III cohorts, respectively.
AC appears beneficial with minimal risk of harm after RPLND, especially in patients with higher risk of developing DVT/PE, highlighting the safety and efficacy of this regimen. There was a significant increase in the rate of AC prophylaxis at discharge amongst patients undergoing RPLND in the institutional database from 2013 to 2022. A risk-stratified protocol of postoperative AC following RPLND appears reasonable, and further prospective trials are warranted to formally confirm this recommendation.
Urologic oncology. 2023 Nov 16 [Epub ahead of print]
Vincent D'Andrea, Zhiyu Jason Qian, Kendrick Yim, Jillian Egan, Christopher J Magnani, Adam Feldman, Keyan Salari, Alok Tewari, Graeme Steele, Matthew Mossanen, Mark Preston, Steven L Chang, Timothy N Clinton
Department of Surgery, Division of Urology, Harvard Medical School, Brigham & Women's Hospital, Boston, MA., Department of Surgery, Division of Urology, Harvard Medical School, Brigham & Women's Hospital, Boston, MA; Department of Urology, Harvard Medical School, Massachusetts General Hospital, Boston, MA., Department of Surgery, Division of Urology, Harvard Medical School, Brigham & Women's Hospital, Boston, MA; Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA., Department of Urology, Harvard Medical School, Massachusetts General Hospital, Boston, MA., Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA., Department of Surgery, Division of Urology, Harvard Medical School, Brigham & Women's Hospital, Boston, MA; Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/37980224